RICTOR and melanoma: Finally, we recently demonstrated a significant reduction of cell motility and liver metastasis by RNAi-mediated suppression of RICTOR in a melanoma mouse model (Schmidt et al., 2018) and a significant decrease of cancer cell motility when targeting mTORC2/RICTOR in addition to rapamycin treatment in gastric cancer cells (Lang et al., 2010).